YFV Protein, Middle East Markets, Gene Editing and "Data Lakes" are among Developments at First Day of AACC 2017 in San Diego

ROCKVILLE, Md., Aug. 1, 2017 /PRNewswire/ -- The laboratory industry's largest meeting, along with associated IVD equipment vendors, are meeting this week in San Diego to discuss new ideas and demonstrate new products.  According to healthcare market researcher Kalorama information, there are already developments at the meeting's first day as companies made announcement and the plenary session was held.   Improved lab developed test equipment, a new yellow fever reagent, the Middle East IVD Market, and promise of CRISPR highlighted the first day of the American Association for Clinical Chemistry Meeting (AACC 2017) in San Diego, California.  The New York City-based healthcare research firm covers IVD in its Worldwide Market for In Vitro Diagnostics, 10th Edition, a comprehensive  in vitro diagnostics market research study. 

Kalorama Information noted the following developments : 

• New YFV Protein: Aalto Bio Reagents announced their first-to-market recombinant Yellow Fever Virus (YFV) protein at AACC in San Diego from 1st - 3rd August. Yellow Fever virus is a potentially fatal mosquito-borne flavivirus which is prevalent in tropical and subtropical locations in South America and Africa.  It is the next flavivirus threatening the population of Brazil, with local health officials reporting a sharp rise in cases this year.  The company, founded in 1978, Aalto Bio Reagents is a developer and provider of raw materials to the in- vitro diagnostics industry and to research laboratories globally.   Infectious disease is one of the most important markets for IVD, and Kalorama covers this extensively in its market study on this area.
• Order-to-Report Multiplex PCR:  Seegene Inc. announced a  Random Access System.  The company says the system can provide order-to-report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.  . Rapid, accurate diagnosis and prompt treatment are especially critical for a successful treatment of infectious diseases such as tuberculosis, acute diarrhea, sepsis or meningitis.   The company said most existing MDx systems are unable to perform same-day reporting for same day treatment, because clinical laboratories typically perform testing after a sufficient number of specimens are collected. 
• Simplified LDT for Leukemia and Lymphoma:   Beckman Coulter presented its ClearLab reagents at the meeting, these products deliver the first preformulated, IVD antibody cocktails for leukemia and lymphoma** immunophenotyping in the clinical lab.  Previously, labs would have had to make and validate their own antibody cocktails. ClearLLab simplifies and standardizes the process.  The products are cleared via the FDA De Novo Process for in vitro diagnostic use in the US.   For clinical laboratories it means they no longer have to develop their own laboratory developed test (LDT), a technically demanding, manual, time-consuming, and potentially error-prone process. 
• Focus on Middle East IVD: Long a target for IVD companies seeking emerging market growth, the Middle East will now have a laboratory association with global pull.  AACC announced on Monday that it will launch a new laboratory medicine conference and expedition next spring – AACC Middle East. AACC Middle East will showcase AACC's globally-renowned education and scientific programs paired with a dynamic exposition in Abu Dhabi, United Arab Emirates (UAE), March 22-24, 2018. The scientific program will feature experts from the U.S. and the Middle East, sharing knowledge and innovation. Attendees will meet and network with experts in the field, and engage with their peers during the scientific program highlighting recent advances in laboratory medicine.  Kalorama's report on the Middle East IVD market can be found at https://www.kaloramainformation.com/IVD-Middle-East-10336235/
• Connected Lab, "Data Lakes":  Roche's booth at AACC 2017 features a virtual reality tour that will demonstrate the company's concept of connected lab . "The idea of a connected lab begins with an integrated core lab with connected automation." said Jack Phillips, president and CEO of Roche Diagnostics Corporation in a press release.  "But it also involves linking instruments to data lakes, laboratories to physicians, and high-medical-value tests to clinical insights to help improve the way physicians manage their patients."  A data lake is a storage repository that holds a vast amount of raw data in its native format and doesn't structure it and define how it will be structured, until the data is needed.  The company is the largest IVD company, according to Kalorama Information and competes in nearly every IVD sub market; while it is also demonstrating a new cobas e 801 high-volume immunoassay platform that Roche says provides nearly twice the throughput on the same footprint as its predecessor.
• CRISPR/ Cas9:  Gene editing was also a large focus at the meeting's first day.  Jennifer Doudna, PhD, a geneticist and a co-creator along with Emmanuelle Carpenter, PhD, of the CRISPR-Cas9 technology, delivered the Wallace H. Coulter Lectureship Award plenary on Sunday with her talk, "CRISPR Biology, Technology & Ethics: The Future of Genome Engineering."   Doudna discussed her "molecular scalpel for genomes." She intrigued the audience by reviewing the intricate bacterial CRISPR adaptive immune system and how her lab harnessed its power to edit genes.  She discussed the work that is ongoing aimed at making CRISPR more amenable to fighting disease.   CRISPR/Cas9 is a revolutionary approach that enables rapid, economical model generation through precise genome editing. Every day, new studies continue to leverage the potential of CRISPR to generate novel strategies for modeling diseases and assessing therapeutic intervention.  The tool is used in nature by bacteria to adapt to their environment.

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.  

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

Press Contact: 
Bruce Carlson
212 807 2262                                                         
[email protected]

View original content with multimedia:http://www.prnewswire.com/news-releases/yfv-protein-middle-east-markets-gene-editing-and-data-lakes--are-among-developments-at-first-day-of-aacc-2017-in-san-diego-300497588.html

SOURCE Kalorama Information

[ Back To TMCnet.com's Homepage ]